Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Br J Clin Pharmacol ; 89(9): 2851-2866, 2023 09.
Artículo en Inglés | MEDLINE | ID: mdl-37160725

RESUMEN

AIM: To evaluate the impact of the COVID-19 pandemic on the patterns of antimicrobial use and the incidence of pathogens in primary and secondary healthcare settings in Northern Ireland. METHODS: Data were collected on antibiotic use and Gram-positive and Gram-negative pathogens from primary and secondary healthcare settings in Northern Ireland for the period before (January 2015-March 2020) and during (April 2020-December 2021) the pandemic. Time series intervention analysis methods were utilized. RESULTS: In the hospital setting, the mean total hospital antibiotic consumption during the pandemic was 1864.5 defined daily doses (DDDs) per 1000 occupied-bed days (OBD), showing no significant change from pre-pandemic (P = .7365). During the pandemic, the use of second-generation cephalosporins, third-generation cephalosporins, co-amoxiclav and levofloxacin increased, there was a decrease in the percentage use of the hospital Access group (P = .0083) and an increase in the percentage use of Watch group (P = .0040), and the number of hospital Klebsiella oxytoca and methicillin-susceptible Staphylococcus aureus cases increased. In primary care, the mean total antibiotic consumption during the COVID-19 pandemic was 20.53 DDDs per 1000 inhabitants per day (DID), compared to 25.56 DID before the COVID-19 pandemic (P = .0071). During the pandemic, there was a decrease in the use of several antibiotic classes, an increase in the percentage use of the Reserve group (P = .0032) and an increase in the number of community-onset Pseudomonas aeruginosa cases. CONCLUSION: This study provides details of both changes in antibiotic consumption and the prevalence of infections in hospitals and primary care before and during the COVID-19 pandemic that emphasize the importance of antimicrobial stewardship in pandemic situations.


Asunto(s)
Antibacterianos , COVID-19 , Humanos , Antibacterianos/uso terapéutico , Pandemias , Prevalencia , Irlanda del Norte/epidemiología , COVID-19/epidemiología , Atención a la Salud , Cefalosporinas
3.
Infection ; 47(5): 781-791, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31065996

RESUMEN

PURPOSE: Use of antibiotics can give rise to the selection of resistant bacteria. It remains unclear whether antibiotic use in primary care can influence bacterial resistance incidence in patients when hospitalised. The aim of this study is to explore the impact of prior community antibiotic usage on hospital-detected multidrug-resistant Gram-negative (MRGN) incidence rate. METHODS: This pharmacoepidemiological study was case-control in design, and was carried out in the Antrim Area Hospital (N. Ireland) in two phases. In phase 1, the controls were matched according to: age, gender, admission ward, date of admission, and age-adjusted Charlson co-morbidity index score. During the second phase, controls were selected randomly from the total population of admissions to the hospital over the 2-year study period. RESULTS: In phase 1, multivariate analysis revealed that prior exposure to the second- and third-generation cephalosporins (p = 0.004) and fluoroquinolones (p = 0.023) in primary care was associated with an increased likelihood of MRGN detection in inpatients. In phase 2, an independent relationship between an increased risk of identification of MRGN, while hospitalised was associated with: prolonged hospitalisation (p < 0.001), being elderly (p < 0.001), being female (p = 0.007), and having genitourinary disease (p < 0.001). CONCLUSION: This study provides clear evidence which supports the need to optimise antibiotic use in primary care to help reduce MRGN incidence in hospitalised patients.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Bacterianas/epidemiología , Infección Hospitalaria/tratamiento farmacológico , Farmacorresistencia Bacteriana Múltiple , Infecciones por Bacterias Gramnegativas/epidemiología , Hospitalización/estadística & datos numéricos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Niño , Preescolar , Infección Hospitalaria/microbiología , Femenino , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Humanos , Incidencia , Lactante , Pacientes Internos , Masculino , Persona de Mediana Edad , Pautas de la Práctica en Medicina , Adulto Joven
4.
Nat Microbiol ; 4(7): 1160-1172, 2019 07.
Artículo en Inglés | MEDLINE | ID: mdl-30962570

RESUMEN

Balancing access to antibiotics with the control of antibiotic resistance is a global public health priority. At present, antibiotic stewardship is informed by a 'use it and lose it' principle, in which antibiotic use by the population is linearly related to resistance rates. However, theoretical and mathematical models suggest that use-resistance relationships are nonlinear. One explanation for this is that resistance genes are commonly associated with 'fitness costs' that impair the replication or transmissibility of the pathogen. Therefore, resistant genes and pathogens may only gain a survival advantage where antibiotic selection pressures exceed critical thresholds. These thresholds may provide quantitative targets for stewardship-optimizing the control of resistance while avoiding over-restriction of antibiotics. Here, we evaluated the generalizability of a nonlinear time-series analysis approach for identifying thresholds using historical prescribing and microbiological data from five populations in Europe. We identified minimum thresholds in temporal relationships between the use of selected antibiotics and incidence rates of carbapenem-resistant Acinetobacter baumannii (Hungary), extended-spectrum ß-lactamase-producing Escherichia coli (Spain), cefepime-resistant E. coli (Spain), gentamicin-resistant Pseudomonas aeruginosa (France) and methicillin-resistant Staphylococcus aureus (Northern Ireland) in different epidemiological phases. Using routinely generated data, our approach can identify context-specific quantitative targets for rationalizing population antibiotic use and controlling resistance. Prospective intervention studies that restrict antibiotic consumption are needed to validate these thresholds.


Asunto(s)
Antibacterianos/normas , Antibacterianos/uso terapéutico , Programas de Optimización del Uso de los Antimicrobianos/normas , Infecciones Bacterianas/tratamiento farmacológico , Farmacorresistencia Bacteriana , Acinetobacter baumannii/efectos de los fármacos , Antibacterianos/farmacología , Programas de Optimización del Uso de los Antimicrobianos/métodos , Infecciones Bacterianas/epidemiología , Infecciones Bacterianas/microbiología , Proteínas Bacterianas/genética , Escherichia coli/efectos de los fármacos , Europa (Continente)/epidemiología , Humanos , Incidencia , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Modelos Teóricos , Pseudomonas aeruginosa/efectos de los fármacos , Factores de Tiempo
5.
Emerg Infect Dis ; 25(1): 52-62, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-30561306

RESUMEN

This quasi-experimental study investigated the effect of an antibiotic cycling policy based on time-series analysis of epidemiologic data, which identified antimicrobial drugs and time periods for restriction. Cyclical restrictions of amoxicillin/clavulanic acid, piperacillin/tazobactam, and clarithromycin were undertaken over a 2-year period in the intervention hospital. We used segmented regression analysis to compare the effect on the incidence of healthcare-associated Clostridioides difficile infection (HA-CDI), healthcare-associated methicillin-resistant Staphylococcus aureus (HA-MRSA), and new extended-spectrum ß-lactamase (ESBL) isolates and on changes in resistance patterns of the HA-MRSA and ESBL organisms between the intervention and control hospitals. HA-CDI incidence did not change. HA-MRSA incidence increased significantly in the intervention hospital. The resistance of new ESBL isolates to amoxicillin/clavulanic acid and piperacillin/tazobactam decreased significantly in the intervention hospital; however, resistance to piperacillin/tazobactam increased after a return to the standard policy. The results question the value of antibiotic cycling to antibiotic stewardship.


Asunto(s)
Programas de Optimización del Uso de los Antimicrobianos/legislación & jurisprudencia , Clostridioides difficile/efectos de los fármacos , Infecciones por Clostridium/epidemiología , Infección Hospitalaria/epidemiología , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Infecciones Estafilocócicas/epidemiología , Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Antibacterianos/uso terapéutico , Clostridioides difficile/enzimología , Infecciones por Clostridium/microbiología , Infección Hospitalaria/microbiología , Farmacorresistencia Bacteriana , Hospitales , Humanos , Incidencia , Staphylococcus aureus Resistente a Meticilina/enzimología , Irlanda del Norte/epidemiología , Infecciones Estafilocócicas/microbiología , beta-Lactamasas/metabolismo
6.
BMC Health Serv Res ; 18(1): 849, 2018 Nov 12.
Artículo en Inglés | MEDLINE | ID: mdl-30419895

RESUMEN

BACKGROUND: To assess antimicrobial prescribing in a Northern Ireland hospital (Antrim Area Hospital (AAH)) and compare them with those of a hospital in Jordan (Specialty Hospital). METHODS: Using the Global-PPS approach, the present study surveyed patients admitted to the hospital in 2015, the prescribed antibiotics, and a set of quality control indicators related to antibiotics. RESULTS: Ultimately, 444 and 112 inpatients in the AAH and the Specialty Hospital, respectively, were surveyed. For the medical group, 165 inpatients were prescribed 239 antibiotics in the AAH, while 44 patients in the Specialty Hospital were prescribed 65 antibiotics. In relation to the surgical group, 34 inpatients treated for infection were prescribed 66 antibiotics in the AAH, while 41 patients in the Specialty Hospital treated for infection were prescribed 56 antibiotics. For the medical patients, the most frequently prescribed antibiotics in the AAH were a combination of penicillins (18.8%) and penicillins with extended spectrum (18.8%). For the surgical patients, the most frequently prescribed antibiotics in the AAH were imidazole derivatives (24.2%). For the medical and surgical patients in the Specialty Hospital, the most frequently prescribed antibiotics were third-generation cephalosporins (26.2 and 37.5%, respectively). In medical patients, compliance to guidelines was 92.2% in the Specialty Hospital compared to 72.0% in the AAH (p < 0.001). In surgical patients, compliance to guidelines was 92.7% in the Specialty Hospital compared to 81.8% in the AAH (p = 0.012). CONCLUSIONS: The present study highlighted differences in the utilisation of antimicrobials between two hospitals in two distinct regions and benchmarked antibiotic prescriptions across two hospitals.


Asunto(s)
Antiinfecciosos/uso terapéutico , Prescripciones de Medicamentos/estadística & datos numéricos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Anciano , Antibacterianos/uso terapéutico , Utilización de Medicamentos , Femenino , Hospitalización/estadística & datos numéricos , Hospitales/estadística & datos numéricos , Humanos , Pacientes Internos/estadística & datos numéricos , Jordania , Masculino , Persona de Mediana Edad , Irlanda del Norte , Penicilinas/uso terapéutico , Prevalencia , Encuestas y Cuestionarios
7.
PLoS One ; 12(8): e0182624, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28787014

RESUMEN

Healthcare acquired infections (HAI) pose a great threat in hospital settings and environmental contamination can be attributed to the spread of these. De-contamination and, significantly, prevention of re-contamination of the environment could help in preventing/reducing this threat. Goldshield (GS5) is a novel organosilane biocide marketed as a single application product with residual biocidal activity. We tested the hypothesis that GS5 could provide longer-term residual antimicrobial activity than existing disinfectants once applied to surfaces. Thus, the residual bactericidal properties of GS5, Actichlor and Distel against repeated challenge with Staphylococcus aureus ATCC43300 were tested, and showed that GS5 alone exhibited longer-term bactericidal activity for up to 6 days on 316I stainless steel surfaces. Having established efficacy against S. aureus, we tested GS5 against common healthcare acquired pathogens, and demonstrated that, on average, a 1 log10 bactericidal effect was exhibited by GS5 treated surfaces, although biocidal activity varied depending upon the surface type and the species of bacteria. The ability of GS5 to prevent Pseudomonas aeruginosa biofilm formation was measured in standard microtitre plate assays, where it had no significant effect on either biofilm formation or development. Taken together the data suggests that GS5 treatment of surfaces may be a useful means to reducing bacterial contamination in the context of infection control practices.


Asunto(s)
Biopelículas/efectos de los fármacos , Biopelículas/crecimiento & desarrollo , Infección Hospitalaria/microbiología , Compuestos de Organosilicio/química , Compuestos de Organosilicio/farmacología , Pseudomonas aeruginosa/efectos de los fármacos , Pseudomonas aeruginosa/fisiología , Antibacterianos/química , Antibacterianos/farmacología , Pruebas de Sensibilidad Microbiana , Propiedades de Superficie
8.
Ulster Med J ; 81(1): 28-9, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23536735

RESUMEN

Mycoplasma pneumoniae (M. pneumoniae) is a common pathogen in cases of atypical pneumonia. Most individuals with Mycoplasma pneumonia run a benign course, with non-specific symptoms of malaise, fever and non-productive cough that usually resolve with no long-term sequelae. Acute lung injury is not commonly seen in Mycoplasma pneumonia. We report a case of acute respiratory distress syndrome cause by M. pneumoniae diagnosed by quantitative real-time polymerase chain reaction (RT-PCR).


Asunto(s)
ADN Bacteriano/análisis , Mycoplasma pneumoniae/aislamiento & purificación , Neumonía por Mycoplasma/diagnóstico , Síndrome de Dificultad Respiratoria/diagnóstico , Adolescente , Antibacterianos/uso terapéutico , Femenino , Humanos , Mycoplasma pneumoniae/genética , Neumonía por Mycoplasma/microbiología , Reacción en Cadena de la Polimerasa , Respiración Artificial , Síndrome de Dificultad Respiratoria/microbiología , Síndrome de Dificultad Respiratoria/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...